Abstract

The terminal complement inhibitor eculizumab has improved the outlook for patients with atypical hemolytic uremic syndrome (aHUS), especially with

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call